

**Company Name :** Xerient Pharma

**Talk Title:** Enhancing radiation therapy for pancreatic cancer patients

**Panel:** The Device is No Longer a Device: Convergence in Medical Technology

**Abstract:**

Xerient Pharma is advancing a novel radioprotective platform centered on the targeted delivery of amifostine directly to the duodenum to enable safer and more effective radiation therapy for pancreatic cancer. While amifostine is an FDA-approved cytoprotective agent, its conventional systemic administration is limited by significant side effects and suboptimal localization; Xerient's approach bypasses gastric degradation and delivers the drug precisely to the duodenum—the gastrointestinal structure most vulnerable to radiation injury in pancreatic cancer treatment. By selectively protecting duodenal tissue, this targeted delivery strategy is designed to unlock the use of higher, potentially curative radiation doses that were previously constrained by toxicity to surrounding organs, thereby addressing a critical limitation in treating unresectable pancreatic tumors. Building on strong preclinical results, Xerient initiated Phase 1/2a clinical studies in 1Q 2026 across three leading U.S. centers to evaluate safety and efficacy, marking an important step toward clinical translation of this precision radioprotection approach.